BIIB Biogen Inc. - Common Stock
$218,71
Prix · Aoû 19, 2026
Données fondamentales au Jul 29, 2026
Fourchette 52 semaines
$132–$220
98% of range
Note des analystes
BUY
43 analysts
Objectif de cours
$236
+8% upside
P/E (TTM)
29.1
ROE
7.2%
Marge nette
13.1%
À propos de Biogen Inc. - Common Stock Présentation de l'entreprise depuis Wikipedia
Biogen est une entreprise américaine cofondée par Walter Gilbert et Charles Weissmann, formée en novembre 2003 par la fusion de deux entreprises spécialisées en biotechnologies : Biogen Inc. et IDEC Pharmaceuticals Corporation.
Lire la suite
Biogen (Biogen Idec jusqu'à 2015) est une entreprise américaine cofondée par Walter Gilbert et Charles Weissmann, formée en novembre 2003 par la fusion de deux entreprises spécialisées en biotechnologies : Biogen Inc. et IDEC Pharmaceuticals Corporation.
Histoire
À la fin des années 1990, Biogen et IDEC Pharmaceuticals Corporation faisaient partie des sociétés devenues célèbres grâce à une bulle des capitalisations boursières sans équivalent dans l'histoire, qui finit en krach, phénomène touchant aussi des nombreuses petites sociétés de Internet, et des Sociétés minières junior, cotées à la Bourse de Vancouver ou de Toronto sans avoir encore extrait une seule tonne de minerai.
En janvier 2015, Biogen acquiert Convergence Pharmaceuticals, une entreprise britannique spécialisée dans les traitements de la douleur chronique, pour 675 millions de dollars.
En mars 2019, Biogen annonce l'acquisition de Nightstar Therapeutics, une entreprise spécialisée dans la thérapie génique, pour 800 millions de dollars.
En 2020, le séminaire d'entreprise qu'elle organise à Boston est accusé d'avoir participé à propager la Covid-19 aux Etats-Unis.
Stratégie
George Scangos, qui a été patron de Biogen à partir de 2010, a décidé d'abandonner le domaine de la cancérologie pour concentrer l'entreprise sur la sclérose en plaques et l’hémophilie.
Michel Vounatsos, patron depuis janvier 2017, décide de recentrer l'entreprise sur les neurosciences, et notamment sur le vieillissement.
Principaux produits
Principaux actionnaires
Au 22 février 2020:
Développements en cours
Maladie de Alzheimer
Biogen développe et teste l'Aducanumab, un anticorps monoclonal qui cible la plaque amyloïde. Après diverses péripéties liées notamment au dosage, le traitement reçoit un bon accueil de la FDA. Cette annonce fait grimper l'action Biogen au Nasdaq de 40% dans la journée du 4 novembre 2020, car l'existence d'un médicament contre Alzheimer représente un marché potentiel de 10 milliards de dollars. Toutefois, un comité d'experts de la FDA désapprouve le traitement 2 jours plus tard. La FDA approuve provisoirement le médicament le 7 juin 2021, tout en demandant à Biogen de mener de nouveaux tests.
Après le relatif échec de ce médicament, l’entreprise place ses espoirs sur le Lecanemab, autorisé par la FDA le 7 janvier 2023, et par l'Agence européenne des médicaments en 2024.
Source : Wikipedia, CC BY-SA 4.0 · Voir sur Wikipedia ↗
BIIB Aperçu de l'action Prix, capitalisation boursière, P/E, EPS, ROE, dette/capitaux propres, fourchette sur 52 semaines
Prix
$218.71
Capitalisation Boursière
$37.49B
P/E (TTM)
29.1
BPA (TTM)
$8.79
Revenus (TTM)
$9.89B
Rendement div.
—
ROE
7.2%
Dette/Capitaux propres
—
Fourchette 52 semaines
$132 – $220
BIIB Graphique du cours de l'action OHLCV quotidien avec indicateurs techniques — panoramique, zoom et personnalisez votre vue
Configure
Performance sur 10 ans Tendances du chiffre d'affaires, du bénéfice net, des marges et du BPA
Revenus et bénéfice net
$9.89B
2016-12-31
→
2025-12-31
BPA
$8.79
2016-12-31
→
2025-12-31
Flux de trésorerie libre
$2.05B
2016-12-31
→
2025-12-31
Marges
13.1%
2016-12-31
→
2020-12-31
Valorisation Ratios P/E, P/S, P/B, EV/EBITDA — l'action est-elle chère ou bon marché ?
Métrique
Tendance sur 5 ans
BIIB
Médiane des pairs
P/E (TTM)
29.1
17.7
P/S (TTM)
3.8
6.8
P/B
2.1
6.4
Price / FCF (Cours / FCF)
18.3
—
Rentabilité Marges brutes, d'exploitation et nettes ; ROE, ROA, ROIC
Métrique
Tendance sur 5 ans
BIIB
Médiane des pairs
Net Profit Margin (Marge nette)
13.1%
20.3%
ROA
4.5%
11.4%
ROE
7.2%
16.8%
Santé financière Dette, liquidité, solvabilité — solidité du bilan
Métrique
Tendance sur 5 ans
BIIB
Médiane des pairs
Current Ratio (Ratio de liquidité)
2.7
3.4
Quick Ratio (Ratio de liquidité réduite)
0.4
—
Croissance Croissance du chiffre d'affaires, du BPA et du bénéfice net : Année/Année, TCAC 3 ans, TCAC 5 ans
Métrique
Tendance sur 5 ans
BIIB
Médiane des pairs
Revenue YoY (Chiffre d'affaires YoY)
2.2%
—
Revenue CAGR 3Y (CAGR du chiffre d'affaires 3 ans)
-0.94%
—
Revenue CAGR 5Y (CAGR du chiffre d'affaires 5 ans)
-6.0%
—
EPS YoY (BPA Année/Année)
-21.4%
—
Net Income YoY (Bénéfice net YoY)
-20.8%
—
Efficacité du capital Rotation des actifs, rotation des stocks, rotation des créances
Métrique
Tendance sur 5 ans
BIIB
Médiane des pairs
BIIB Consensus des analystes Opinions des analystes haussières et baissières, objectif de cours à 12 mois, potentiel de hausse
ACHAT
43 analystes
- Achat fort 9 20,9%
- Achat 20 46,5%
- Conserver 13 30,2%
- Vente 1 2,3%
- Vente forte 0 0,0%
Objectif de cours à 12 mois
31 analystes · 2026-08-13
Médiane
$237.00
Maintenant
$218.71
Bas
$165.00
Haut
$300.00
Objectif médian
$237.00
+8,4%
Objectif moyen
$235.57
+7,7%
Historique des bénéfices BPA réel vs estimation, surprise %, taux de succès, prochaine date de publication des résultats
Surprise Moyenne
0.75%
| Période | EPS Actual | BPA est. | Surprise |
|---|---|---|---|
| 30 juin 2026 | $3.60 | $3.01 | 0.59% |
| 31 mars 2026 | $3.57 | $2.83 | 0.74% |
| 31 décembre 2025 | $1.99 | $1.65 | 0.34% |
| 30 septembre 2025 | $4.81 | $3.96 | 0.85% |
| 30 juin 2025 | $5.47 | $3.94 | 1.5% |
| 31 mars 2025 | $3.02 | $2.58 | 0.44% |
Comparaison des pairs (sous-secteur GICS) Indicateurs clés par rapport aux pairs du secteur
| Ticker | Capitalisation Boursière | P/E | Revenus Année/Année | Marge Nette | ROE | Marge Brute |
|---|---|---|---|---|---|---|
| BIIB | $25.84B | 20.0 | 2.2% | 13.1% | 7.2% | — |
| VRTX | $115.15B | 29.6 | 8.9% | 32.9% | 22.1% | — |
| REGN | $106.21B | 18.6 | 0.99% | 31.4% | 14.7% | — |
| RVMD | — | — | — | — | — | — |
| NTRA | $32.00B | -150.7 | 35.9% | -9.0% | -14.1% | — |
| ALNY | $52.64B | 170.7 | 65.2% | 8.5% | 60.4% | — |
| INSM | $37.29B | -27.1 | 66.7% | -210.5% | -128.4% | — |
| INCY | $19.60B | 15.4 | 21.2% | 25.0% | 27.6% | — |
| MRNA | $11.62B | -4.1 | -39.9% | -145.2% | -31.3% | — |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
Fondamentaux complets Tous les indicateurs par an — compte de résultat, bilan, flux de trésorerie
Compte de résultat 17
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.89B | $9.68B | $9.84B | $10.17B | $10.98B | $13.44B | $14.38B | $13.45B | $12.27B | $11.45B | $10.76B | $9.70B | |
| Cost of Revenue | $2.40B | $2.31B | $2.53B | $2.28B | $2.11B | $1.81B | $1.96B | $1.82B | $1.63B | $1.48B | $1.24B | $1.17B | |
| Gross Profit | · | · | · | · | · | $11.64B | $12.42B | $11.64B | $10.64B | $9.97B | $9.52B | $8.53B | |
| SG&A Expense | $2.43B | $2.40B | $2.55B | $2.40B | $2.67B | $2.50B | $2.37B | $2.11B | $1.93B | $1.95B | $2.11B | $2.23B | |
| Operating Expenses | $8.33B | $7.77B | $8.54B | $6.58B | $9.24B | $8.40B | $7.34B | $7.56B | $6.93B | $6.30B | $5.87B | $5.75B | |
| Operating Income | · | · | · | · | $2.84B | $4.55B | $7.04B | $5.89B | $5.35B | $5.15B | $4.89B | $3.97B | |
| Interest Expense | $268M | $250M | $247M | $247M | $254M | $222M | $187M | $201M | $251M | $260M | $96M | $30M | |
| Interest Income | $125M | $68M | $276M | $89M | $11M | $42M | $120M | $112M | $78M | $63M | $22M | $12M | |
| Other Non-op | $-25M | $3M | $-400.0K | $10M | $6M | $-3M | $-47M | $-10M | $-15M | $-18M | $-14M | $-26M | |
| Pretax Income | $1.56B | $1.91B | $1.30B | $3.59B | $1.75B | $5.05B | $7.13B | $5.90B | $5.13B | $4.93B | $4.77B | $3.95B | |
| Income Tax | $264M | $274M | $135M | $633M | $52M | $992M | $1.16B | $1.43B | $2.46B | $1.24B | $1.16B | $990M | |
| Net Income | $1.29B | $1.63B | $1.16B | $3.05B | $1.56B | $4.00B | $5.89B | $4.43B | $2.54B | $3.70B | $3.55B | $2.93B | |
| EPS (Basic) | $8.83 | $11.21 | $8.02 | $20.96 | $10.44 | $24.86 | $31.47 | $21.63 | $11.94 | $16.96 | $15.38 | $12.42 | |
| EPS (Diluted) | $8.79 | $11.18 | $7.97 | $20.87 | $10.40 | $24.80 | $31.42 | $21.58 | $11.92 | $16.93 | $15.34 | $12.37 | |
| Shares (Basic) | 146,500,000 | 145,600,000 | 144,700,000 | 145,300,000 | 149,100,000 | 160,900,000 | 187,100,000 | 204,900,000 | 212,600,000 | 218,400,000 | 230,700,000 | 236,400,000 | |
| Shares (Diluted) | 147,100,000 | 145,900,000 | 145,600,000 | 146,000,000 | 149,600,000 | 161,300,000 | 187,400,000 | 205,300,000 | 213,000,000 | 218,800,000 | 231,200,000 | 237,200,000 | |
| EBITDA | $780M | $673M | $495M | $518M | $3.33B | $5.01B | $7.72B | $6.91B | $6.43B | $5.83B | $5.49B | $4.66B |
Bilan 29
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | · | · | · | · | · | · | $2.91B | $1.22B | $1.57B | $2.33B | $1.31B | $1.20B | |
| Short-term Investments | · | · | · | · | · | · | $1.56B | $2.31B | $2.12B | $2.57B | $2.12B | $640M | |
| Receivables | $1.34B | $1.40B | $1.66B | $1.71B | $1.55B | $1.91B | $1.88B | $1.96B | $1.79B | $1.44B | $1.23B | $1.29B | |
| Inventory | $2.17B | $2.46B | $2.53B | $1.34B | $1.35B | $1.07B | $804M | $930M | $903M | $1.00B | $893M | $804M | |
| Other Current Assets | $1.12B | $752M | $1.18B | $1.42B | $741M | $881M | $631M | $688M | $962M | $1.09B | $837M | $310M | |
| Current Assets | $8.97B | $7.46B | $6.86B | $9.79B | $7.86B | $6.89B | $8.38B | $7.64B | $7.87B | $8.73B | $6.70B | $4.54B | |
| PP&E (Net) | $3.06B | $3.18B | $3.31B | $3.30B | $3.42B | $3.41B | $3.25B | $3.60B | $3.18B | $2.50B | $2.19B | $1.77B | |
| PP&E (Gross) | $5.99B | $5.85B | $5.71B | $5.46B | $5.42B | $5.19B | $4.84B | $5.40B | $4.74B | $3.94B | $3.52B | $2.95B | |
| Accum. Depreciation | $2.90B | $2.67B | $2.40B | $2.17B | $2.01B | $1.78B | $1.59B | $1.80B | $1.56B | $1.44B | $1.33B | $1.19B | |
| Goodwill | $6.49B | $6.48B | $6.22B | $5.75B | $5.76B | $5.76B | $5.76B | $5.71B | $4.63B | $3.67B | $2.66B | $1.76B | |
| Intangibles | $9.18B | $9.69B | $8.36B | $1.85B | $2.22B | $3.08B | $3.53B | $3.12B | $3.88B | $3.81B | $4.09B | $4.03B | |
| Other Non-current Assets | $751M | $560M | $745M | $1.53B | $1.94B | $2.90B | $1.25B | $1.69B | $432M | $1.34B | $1.11B | $755M | |
| Total Assets | $29.44B | $28.05B | $26.84B | $24.55B | $23.88B | $24.62B | $27.23B | $25.29B | $23.65B | $22.88B | $19.50B | $14.31B | |
| Accounts Payable | $432M | $424M | $403M | $492M | $589M | $455M | $531M | $370M | $396M | $280M | $267M | $229M | |
| Short-term Debt | · | $1.75B | $150M | $0 | $999M | $0 | $1.50B | $0 | · | · | · | · | |
| Current Liabilities | $3.35B | $5.53B | $3.43B | $3.27B | $4.30B | $3.74B | $4.86B | $3.30B | $3.37B | $3.42B | $2.58B | $2.22B | |
| Capital Leases | $290M | $334M | $400M | $333M | $330M | $402M | $413M | $0 | · | · | · | · | |
| Deferred Tax | $508M | $190M | $642M | $335M | $694M | $1.03B | $2.81B | $1.64B | $123M | $93M | $125M | $52M | |
| Other Non-current Liabilities | $748M | $732M | $781M | $944M | $1.32B | $1.33B | $1.35B | $1.39B | $1.63B | $722M | $906M | $650M | |
| Total Liabilities | $11.18B | $11.33B | $12.05B | $11.17B | $12.92B | $13.93B | $13.90B | $12.26B | $11.05B | $10.75B | $10.13B | $3.50B | |
| Long-term Debt | $6.29B | $4.55B | $6.79B | $6.28B | $6.27B | $7.43B | $4.46B | $5.94B | $5.93B | $6.51B | $6.52B | $580M | |
| Common Stock | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | |
| Paid-in Capital | $863M | $569M | $302M | $73M | $68M | $0 | $0 | $0 | $98M | $0 | $0 | $4.20B | |
| Retained Earnings | $20.55B | $19.26B | $17.63B | $16.47B | $13.91B | $13.98B | $16.46B | $16.26B | $15.81B | $15.07B | $12.21B | $9.28B | |
| Treasury Stock | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.61B | $2.61B | $2.61B | |
| AOCI | $-182M | $-136M | $-154M | $-165M | $-107M | $-299M | $-135M | $-240M | $-318M | $-320M | $-224M | $-60M | |
| Stockholders' Equity | $18.26B | $16.72B | $14.80B | $13.39B | $10.96B | $10.70B | $13.34B | $13.04B | $12.61B | $12.14B | $9.37B | $10.81B | |
| Liabilities + Equity | $29.44B | $28.05B | $26.84B | $24.55B | $23.88B | $24.62B | $27.23B | $25.29B | $23.65B | $22.88B | $19.50B | $14.31B | |
| Shares Outstanding | 170,500,000 | 169,500,000 | 144,900,000 | 167,900,000 | 170,800,000 | 176,200,000 | 174,200,000 | 197,200,000 | 211,500,000 | 215,900,000 | 218,600,000 | 234,600,000 |
Flux de trésorerie 18
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $780M | $673M | $495M | $518M | $488M | $457M | $465M | $650M | $1.08B | $683M | $600M | $688M | |
| Stock-based Comp | $291M | $291M | $264M | $254M | $239M | $198M | $182M | $158M | $128M | $155M | $161M | $155M | |
| Deferred Tax | $362M | $-158M | $-306M | $-169M | $-427M | $149M | $67M | $108M | $92M | $-175M | $-146M | $-308M | |
| Amort. of Intangibles | $507M | $386M | $241M | $246M | $252M | $255M | $274M | $381M | $455M | $373M | $383M | $490M | |
| Restructuring | $49M | $30M | $219M | $131M | $0 | $0 | $2M | $12M | $900.0K | $33M | $93M | $0 | |
| Other Non-cash | $-521M | $437M | $-67M | $-2.27B | $1.78B | $-575M | $260M | $475M | $711M | $157M | $-447M | $-528M | |
| Operating Cash Flow | $2.20B | $2.88B | $1.55B | $1.38B | $3.64B | $4.23B | $7.08B | $6.19B | $4.55B | $4.59B | $3.92B | $2.94B | |
| CapEx | $154M | $154M | $277M | $240M | $258M | $425M | $514M | $771M | $867M | $616M | $643M | $288M | |
| Investing Cash Flow | $-1.37B | $-799M | $-4.10B | $1.58B | $-564M | $-609M | $470M | $-2.05B | $-2.96B | $-2.48B | $-4.55B | $-1.54B | |
| Debt Issued | $1.73B | $0 | $997M | $0 | $0 | $2.97B | $0 | $0 | · | · | · | · | |
| Net Debt Issued | $-17M | $0 | $997M | $0 | $0 | $2.97B | · | · | · | · | · | · | |
| Stock Repurchased | · | $0 | $0 | $750M | $1.80B | $6.68B | $5.87B | $4.35B | $1.37B | $1.00B | $5.00B | $887M | |
| Net Stock Activity | · | $0 | $0 | $-750M | $-1.80B | $-6.68B | $-5.87B | $-4.35B | $-1.37B | $-1.00B | $-5.00B | $-887M | |
| Financing Cash Flow | $-302M | $-684M | $149M | $-1.75B | $-2.09B | $-5.27B | $-5.86B | $-4.47B | $-2.38B | $-1.05B | $783M | $-756M | |
| Net Change in Cash | · | · | · | · | · | · | · | · | $-792M | $1.05B | $149M | $643M | |
| Taxes Paid | $864M | $355M | $741M | $933M | $248M | $907M | $1.06B | $1.01B | $1.07B | $1.64B | $1.67B | $1.16B | |
| Free Cash Flow | $2.05B | $2.72B | $1.27B | $1.14B | $3.38B | $3.81B | $6.56B | $5.42B | $3.68B | $3.91B | $3.07B | $2.65B | |
| Levered FCF | $1.83B | $2.51B | $1.05B | $941M | $3.14B | $3.63B | $6.41B | $5.26B | $3.55B | $3.71B | $3.00B | $2.63B |
Rentabilité 8
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | 86.6% | 86.4% | 86.5% | 86.7% | 87.1% | 88.5% | 87.9% | |
| Operating Margin | · | · | · | · | 25.9% | 33.8% | 49.0% | 43.8% | 43.5% | 45.0% | 45.4% | 40.9% | |
| Net Margin | 13.1% | 16.9% | 11.8% | 29.9% | 14.2% | 29.8% | 41.0% | 32.9% | 20.7% | 32.3% | 33.0% | 30.2% | |
| Pretax Margin | 15.7% | 19.7% | 13.2% | 35.3% | 15.9% | 37.5% | 49.6% | 43.9% | 41.8% | 43.1% | 44.3% | 40.7% | |
| EBITDA Margin | 7.9% | 7.0% | 5.0% | 5.1% | 30.3% | 37.2% | 53.7% | 51.3% | 52.3% | 50.9% | 51.0% | 48.0% | |
| ROA | 4.5% | 5.9% | 4.5% | 12.6% | 6.4% | 15.4% | 22.4% | 18.1% | 10.9% | 17.5% | 21.0% | 22.4% | |
| ROE | 7.2% | 9.9% | 7.9% | 25.0% | 14.4% | 33.3% | 44.8% | 33.1% | 20.5% | 34.4% | 35.1% | 30.2% | |
| ROIC | · | · | · | · | 25.3% | 34.2% | 44.2% | 34.2% | 22.1% | 31.8% | 39.5% | 27.5% |
Liquidité et Solvabilité 3
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.7 | 1.3 | 2.0 | 3.0 | 1.8 | 1.8 | 1.7 | 2.3 | 2.3 | 2.6 | 2.6 | 2.1 | |
| Quick Ratio | 0.4 | 0.3 | 0.5 | 0.5 | 0.4 | 0.5 | 1.3 | 1.7 | 1.6 | 1.9 | 1.8 | 1.4 | |
| Interest Coverage | · | · | · | · | 11.2 | 20.4 | 37.6 | 29.4 | 21.3 | 19.8 | 51.2 | 134.7 |
Efficacité 3
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.4 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.6 | 0.7 | |
| Inventory Turnover | 1.0 | 0.9 | 1.3 | 1.7 | 1.7 | 1.9 | 2.3 | 2.0 | 1.7 | 1.6 | 1.5 | 1.6 | |
| Receivables Turnover | 7.2 | 6.3 | 5.8 | 6.3 | 6.3 | 7.1 | 7.5 | 7.2 | 7.6 | 8.6 | 8.5 | 9.2 |
Taux de croissance 9
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 2.2% | -1.6% | -3.3% | -7.4% | -18.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -0.94% | -4.1% | -9.9% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -6.0% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -21.4% | 40.3% | -61.8% | 100.7% | -58.1% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | -25.0% | 2.4% | -31.5% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -18.7% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -20.8% | 40.6% | -61.9% | 95.8% | -61.1% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | -24.9% | 1.6% | -33.8% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -20.2% | · | · | · | · | · | · | · | · | · | · | · |
Valorisation (TTM) 10
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $9.89B | $9.68B | $9.84B | $10.17B | $10.98B | $13.44B | $14.38B | $13.45B | $12.27B | $11.45B | $10.76B | $9.70B | |
| Net Income TTM | $1.29B | $1.63B | $1.16B | $3.05B | $1.56B | $4.00B | $5.89B | $4.43B | $2.54B | $3.70B | $3.55B | $2.93B | |
| Market Cap | $25.84B | $22.30B | $37.50B | $39.88B | $35.27B | $37.32B | $51.69B | $59.34B | $67.38B | $61.22B | $66.97B | $79.62B | |
| P/E | 20.0 | 13.7 | 32.5 | 13.3 | 23.1 | 9.9 | 9.4 | 13.9 | 26.7 | 16.8 | 20.0 | 27.4 | |
| P/S | 2.6 | 2.3 | 3.8 | 3.9 | 3.2 | 2.8 | 3.6 | 4.4 | 5.5 | 5.3 | 6.2 | 8.2 | |
| P/B | 1.4 | 1.3 | 2.5 | 3.0 | 3.2 | 3.5 | 3.9 | 4.6 | 5.3 | 5.0 | 7.1 | 7.4 | |
| P / Tangible Book | 10.0 | 40.8 | 172.6 | 6.9 | 11.8 | 20.1 | · | · | · | · | · | · | |
| P / Cash Flow | 11.7 | 7.8 | 24.2 | 28.8 | 9.7 | 8.8 | 7.3 | 9.6 | 14.8 | 13.5 | 18.0 | 27.1 | |
| P / FCF | 12.6 | 8.2 | 29.5 | 34.9 | 10.4 | 9.8 | 7.9 | 11.0 | 18.3 | 15.7 | 21.8 | 30.0 | |
| Earnings Yield | 5.0% | 7.3% | 3.1% | 7.5% | 4.3% | 10.1% | 10.6% | 7.2% | 3.7% | 6.0% | 5.0% | 3.6% |
Compte de résultat 15
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.74B | $2.48B | $2.28B | $2.53B | $2.65B | $2.43B | $2.45B | $2.47B | $2.46B | $2.29B | $2.39B | $2.53B | $2.46B | $2.46B | $2.54B | $2.51B | |
| Cost of Revenue | $777M | $661M | $496M | $674M | $605M | $629M | $584M | $639M | $546M | $542M | $618M | $660M | $593M | $663M | $571M | $470M | |
| SG&A Expense | $710M | $607M | $682M | $595M | $584M | $572M | $680M | $588M | $554M | $582M | $608M | $788M | $548M | $605M | $633M | $563M | |
| Operating Expenses | $2.60B | $2.10B | $2.34B | $1.98B | $1.90B | $2.12B | $2.16B | $2.01B | $1.77B | $1.83B | $2.09B | $2.67B | $1.75B | $2.02B | $1.94B | $1.14B | |
| Interest Expense | $82M | $68M | $68M | $67M | $73M | $60M | $60M | $60M | $61M | $69M | $72M | $64M | $49M | $62M | $55M | $60M | |
| Interest Income | $25M | $38M | $37M | $32M | $32M | $24M | $18M | $12M | $20M | $17M | $24M | $96M | $76M | $81M | $50M | $24M | |
| Other Non-op | $3M | $-1M | $-37M | $16M | $2M | $2M | $8M | $-800.0K | $-2M | $-2M | $5M | $-3M | $-2M | $600.0K | $35M | $2M | |
| Pretax Income | $132M | $378M | $-56M | $557M | $744M | $311M | $292M | $451M | $699M | $465M | $292M | $-141M | $708M | $438M | $604M | $1.37B | |
| Income Tax | $35M | $58M | $-7M | $91M | $109M | $71M | $25M | $62M | $115M | $71M | $43M | $-73M | $115M | $51M | $54M | $236M | |
| Net Income | $98M | $320M | $-49M | $466M | $635M | $240M | $267M | $388M | $584M | $393M | $250M | $-68M | $592M | $388M | $550M | $1.13B | |
| EPS (Basic) | $0.66 | $2.17 | $-0.33 | $3.18 | $4.33 | $1.65 | $1.82 | $2.67 | $4.01 | $2.71 | $1.71 | $-0.47 | $4.09 | $2.69 | $3.79 | $7.86 | |
| EPS (Diluted) | $0.66 | $2.15 | $-0.35 | $3.17 | $4.33 | $1.64 | $1.82 | $2.66 | $4.00 | $2.70 | $1.70 | $-0.47 | $4.07 | $2.67 | $3.73 | $7.84 | |
| Shares (Basic) | 147,700,000 | 147,200,000 | -292,700,000 | 146,600,000 | 146,500,000 | 146,100,000 | -290,900,000 | 145,700,000 | 145,600,000 | 145,200,000 | -289,200,000 | 144,800,000 | 144,700,000 | 144,400,000 | -292,100,000 | 144,400,000 | |
| Shares (Diluted) | 148,700,000 | 148,400,000 | -293,300,000 | 147,100,000 | 146,700,000 | 146,600,000 | -292,000,000 | 146,100,000 | 145,900,000 | 145,900,000 | -289,900,000 | 144,800,000 | 145,500,000 | 145,200,000 | -292,600,000 | 144,800,000 | |
| EBITDA | · | $204M | · | · | · | $183M | · | · | · | $148M | · | · | · | $112M | · | · |
Bilan 28
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Receivables | · | · | $1.34B | · | · | · | $1.40B | · | · | · | · | · | · | $1.63B | · | $1.57B | |
| Inventory | $2.38B | $1.95B | $2.17B | $2.21B | $2.27B | $2.27B | $2.46B | $2.47B | $2.51B | $2.52B | · | $2.98B | $1.33B | $1.28B | · | $1.38B | |
| Other Current Assets | $1.24B | $1.17B | $1.12B | $917M | $851M | $757M | $752M | $674M | $615M | $1.17B | · | $974M | $896M | $1.41B | · | $1.50B | |
| Current Assets | $7.31B | $9.19B | $8.97B | $8.94B | $7.97B | $7.63B | $7.46B | $6.83B | $7.11B | $6.76B | · | $8.45B | $10.43B | $9.76B | · | $9.77B | |
| PP&E (Net) | $2.99B | $3.02B | $3.06B | $3.08B | $3.10B | $3.13B | $3.18B | $3.21B | $3.25B | $3.28B | · | $3.30B | $3.31B | $3.30B | · | $3.27B | |
| PP&E (Gross) | · | · | $5.99B | · | · | · | $5.85B | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | $3.10B | $3.00B | $2.93B | $2.87B | $2.81B | $2.74B | $2.67B | $2.60B | $2.54B | $2.47B | · | $2.34B | $2.28B | $2.22B | · | $2.10B | |
| Goodwill | $6.99B | $6.49B | $6.49B | $6.49B | $6.49B | $6.48B | $6.48B | $6.49B | $6.23B | $6.23B | $6.22B | $6.81B | $5.75B | $5.75B | $5.75B | $5.74B | |
| Intangibles | $13.52B | $9.05B | $9.18B | $9.33B | $9.47B | $9.58B | $9.69B | $9.81B | $8.23B | $8.28B | · | $7.34B | $1.78B | $1.81B | · | $2.01B | |
| Other Non-current Assets | $832M | $778M | $751M | $730M | $638M | $559M | $560M | $631M | $682M | $698M | · | $755M | $1.10B | $1.38B | · | $1.61B | |
| Total Assets | $32.09B | $29.48B | $29.44B | $29.21B | $28.33B | $28.03B | $28.05B | $28.31B | $26.80B | $26.57B | · | $28.19B | $25.16B | $24.60B | · | $24.85B | |
| Accounts Payable | $404M | $358M | $432M | $413M | $408M | $392M | $424M | $423M | $354M | $387M | · | $440M | $445M | $491M | · | $383M | |
| Short-term Debt | · | · | · | $0 | $0 | $1.75B | · | $1.75B | $0 | $250M | · | $500M | · | · | · | $0 | |
| Current Liabilities | $3.92B | $3.00B | $3.35B | $3.29B | $3.18B | $5.30B | $5.53B | $5.42B | $3.11B | $3.22B | · | $5.02B | $3.19B | $3.01B | · | $3.93B | |
| Capital Leases | $265M | $273M | $290M | $305M | $311M | $323M | $334M | $357M | $368M | $406M | · | $429M | $304M | $327M | · | $355M | |
| Deferred Tax | $946M | $484M | $508M | $358M | $118M | $133M | $190M | $882M | $591M | $658M | · | $728M | $144M | $251M | · | $329M | |
| Other Non-current Liabilities | $821M | $787M | $748M | $762M | $800M | $752M | $732M | $744M | $557M | $777M | · | $748M | $777M | $936M | · | $1.20B | |
| Total Liabilities | $13.24B | $10.83B | $11.18B | $11.00B | $10.70B | $11.05B | $11.33B | $11.95B | $10.91B | $11.35B | · | $13.71B | $10.70B | $10.81B | · | $12.09B | |
| Long-term Debt | $7.29B | $6.29B | $6.29B | $6.29B | $6.28B | $4.55B | · | $4.55B | $6.29B | $6.29B | · | $6.79B | $6.28B | $6.28B | · | $6.28B | |
| Total Debt | · | · | · | $0 | $0 | $1.75B | · | $1.75B | $0 | $250M | · | $500M | · | · | · | $0 | |
| Common Stock | $100.0K | $100.0K | · | $100.0K | $100.0K | $100.0K | · | $100.0K | $100.0K | $100.0K | · | $100.0K | $100.0K | $100.0K | · | $100.0K | |
| Paid-in Capital | $983M | $897M | $863M | $798M | $714M | $630M | $569M | $488M | $408M | $330M | · | $242M | $171M | $91M | · | $0 | |
| Retained Earnings | $20.97B | $20.87B | $20.55B | $20.60B | $20.14B | $19.50B | $19.26B | $18.99B | $18.60B | $18.02B | · | $17.38B | $17.45B | $16.85B | · | $15.92B | |
| Treasury Stock | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | · | $2.98B | $2.98B | $2.98B | · | $2.98B | |
| AOCI | $-128M | $-140M | $-182M | $-215M | $-238M | $-174M | $-136M | $-146M | $-146M | $-160M | · | $-159M | $-173M | $-172M | · | $-164M | |
| Stockholders' Equity | $18.85B | $18.65B | $18.26B | $18.21B | $17.63B | $16.98B | $16.72B | $16.36B | $15.89B | $15.21B | $14.80B | $14.48B | $14.47B | $13.80B | $13.39B | $12.78B | |
| Liabilities + Equity | $32.09B | $29.48B | $29.44B | $29.21B | $28.33B | $28.03B | $28.05B | $28.31B | $26.80B | $26.57B | · | $28.19B | $25.16B | $24.60B | · | $24.85B | |
| Shares Outstanding | 171,500,000 | 171,400,000 | 146,800,000 | 170,500,000 | 170,400,000 | 170,300,000 | 145,800,000 | 169,500,000 | 169,500,000 | 169,400,000 | 144,900,000 | 168,700,000 | 168,600,000 | 168,600,000 | 144,000,000 | 167,800,000 |
Flux de trésorerie 15
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $236M | $204M | $200M | $202M | $194M | $183M | $184M | $183M | $159M | $148M | $140M | $125M | $117M | $112M | $120M | $121M | |
| Stock-based Comp | $77M | $84M | $60M | $75M | $75M | $81M | $75M | $73M | $71M | $73M | $55M | $62M | $72M | $76M | $67M | $64M | |
| Deferred Tax | $-28M | $24M | $167M | $254M | $-31M | $-28M | $-58M | $-53M | $-87M | $40M | $72M | $-207M | $-106M | $-64M | $-29M | $-92M | |
| Amort. of Intangibles | $168M | · | $132M | $136M | $127M | · | $111M | $110M | $87M | · | · | · | · | · | · | · | |
| Restructuring | $165M | $8M | $7M | $7M | $-700.0K | $35M | $5M | $7M | $7M | $12M | $99M | $76M | $34M | $10M | $7M | $15M | |
| Other Non-cash | · | $14M | · | · | · | $-218M | · | · | · | $-100M | · | · | · | $-56M | · | · | |
| Operating Cash Flow | $449M | $646M | $512M | $1.27B | $161M | $259M | $761M | $936M | $626M | $553M | $12M | $592M | $487M | $455M | $-175M | $661M | |
| CapEx | $41M | $51M | $44M | $46M | $27M | $37M | $39M | $35M | $34M | $46M | $65M | $74M | $71M | $67M | $86M | $59M | |
| Investing Cash Flow | $-3.84B | $-210M | $-1.23B | $-35M | $-57M | $-47M | $-19M | $-1.18B | $466M | $-66M | $-652M | $-1.74B | $-754M | $-953M | $-141M | $1.67B | |
| Debt Issued | · | · | $0 | $-300.0K | · | · | $0 | $0 | · | · | $0 | · | · | · | $0 | · | |
| Net Debt Issued | · | · | · | · | · | $0 | · | · | · | $-400M | · | · | · | · | · | · | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | $0 | $250M | |
| Financing Cash Flow | $1.30B | $-44M | $-137M | $-130M | $-12M | $-23M | $8M | $-7M | $-245M | $-440M | $-646M | $849M | $-10M | $-43M | $-7M | $-1.25B | |
| Free Cash Flow | · | $594M | · | · | · | $222M | · | · | · | $507M | · | · | · | $389M | · | · | |
| Levered FCF | · | $537M | · | · | · | $176M | · | · | · | $449M | · | · | · | $333M | · | · |
Rentabilité 5
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 3.6% | 12.9% | · | 18.4% | 24.0% | 9.9% | · | 15.8% | 23.7% | 17.2% | · | -2.7% | 24.1% | 15.8% | · | 45.2% | |
| Pretax Margin | 4.8% | 15.2% | · | 22.0% | 28.1% | 12.8% | · | 18.3% | 28.3% | 20.3% | · | -5.6% | 28.8% | 17.8% | · | 54.7% | |
| EBITDA Margin | · | 8.2% | · | · | · | 7.5% | · | · | · | 6.4% | · | · | · | 4.6% | · | · | |
| ROA | 0.32% | 1.1% | · | 1.6% | 2.3% | 0.88% | · | 1.4% | 2.2% | 1.5% | · | -0.26% | 2.4% | 1.6% | · | 4.7% | |
| ROE | 0.53% | 1.8% | · | 2.7% | 3.8% | 1.5% | · | 2.5% | 3.9% | 2.7% | · | -0.50% | 4.7% | 3.0% | · | 9.8% |
Liquidité et Solvabilité 3
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.9 | 3.1 | · | 2.7 | 2.5 | 1.4 | · | 1.3 | 2.3 | 2.1 | · | 1.7 | 3.3 | 3.2 | · | 2.5 | |
| Quick Ratio | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.5 | · | 0.4 | |
| Debt / Equity | · | · | · | 0.0 | 0.0 | 0.1 | · | 0.1 | 0.0 | 0.0 | · | 0.0 | · | · | · | 0.0 |
Efficacité 3
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.2 | 0.3 | 0.3 | · | 0.3 | 0.5 | 0.5 | · | 0.3 | |
| Receivables Turnover | · | · | · | · | · | · | · | · | · | · | · | · | · | 1.5 | · | 1.5 |
Valorisation (TTM) 10
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $10.39B | $10.09B | · | $10.08B | $10.01B | $9.65B | · | $9.75B | $9.74B | $9.74B | · | $9.96B | $10.02B | $10.09B | · | $10.41B | |
| Net Income TTM | $1.52B | $1.66B | · | $1.73B | $1.85B | $1.61B | · | $1.30B | $1.50B | $1.30B | · | $2.05B | $3.17B | $2.88B | · | $2.83B | |
| Market Cap | $37.05B | $31.42B | · | $23.88B | $21.40B | $23.30B | · | $32.86B | $39.29B | $36.53B | · | $43.36B | $48.03B | $46.88B | · | $44.80B | |
| P/E | 21.0 | 16.2 | · | 11.9 | 9.9 | 12.4 | · | 21.8 | 22.5 | 24.0 | · | 18.2 | 13.1 | 14.0 | · | 13.8 | |
| P/S | 3.6 | 3.1 | · | 2.4 | 2.1 | 2.4 | · | 3.4 | 4.0 | 3.8 | · | 4.4 | 4.8 | 4.6 | · | 4.3 | |
| P/B | 2.0 | 1.7 | · | 1.3 | 1.2 | 1.4 | · | 2.0 | 2.5 | 2.4 | · | 3.0 | 3.3 | 3.4 | · | 3.5 | |
| P / Tangible Book | · | 10.1 | · | 10.0 | 12.8 | 25.4 | · | 486.0 | 27.5 | 52.1 | · | 130.7 | 6.9 | 7.5 | · | 8.9 | |
| P / Cash Flow | · | 48.7 | · | · | · | 89.9 | · | · | · | 66.0 | · | · | · | 103.0 | · | · | |
| P / FCF | · | 52.9 | · | · | · | 104.9 | · | · | · | 72.0 | · | · | · | 120.6 | · | · | |
| Earnings Yield | 4.8% | 6.2% | · | 8.4% | 10.1% | 8.0% | · | 4.6% | 4.4% | 4.2% | · | 5.5% | 7.7% | 7.1% | · | 7.2% |
États financiers Compte de résultat, bilan, flux de trésorerie — annuel, sur les 5 dernières années
Compte de résultat
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Revenu | $9.89B | $9.68B | $9.84B | $10.17B | $10.98B |
| Marge d'exploitation % | — | — | — | — | 25.9% |
| Résultat net | $1.29B | $1.63B | $1.16B | $3.05B | $1.56B |
| BPA dilué | $8.79 | $11.18 | $7.97 | $20.87 | $10.40 |
Bilan
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ratio de liquidité | 2.7 | 1.3 | 2.0 | 3.0 | 1.8 |
| Ratio de liquidité réduite | 0.4 | 0.3 | 0.5 | 0.5 | 0.4 |
Flux de trésorerie
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flux de trésorerie libre | $2.05B | $2.72B | $1.27B | $1.14B | $3.38B |
Dernières actualités Actualités récentes mentionnant cette entreprise
- What Makes Denali Therapeutics (DNLI) One of the Best AI Driven Biotech Names
- Biogen fait avancer un médicament contre la maladie d'Alzheimer vers un essai de phase avancée malgré des données décevantes
- Pourquoi l'action Biogen a été gagnante mercredi
- Voici les principaux appels de recherche des analystes de Wall Street pour mardi : Biogen, Birkenstock, Fastly, Ford, Lennox International, Netskope, SanDisk, Tesla, et plus encore
- Pourquoi l'action Biogen a été écrasée lundi
- Apellis Pharma s'envole suite à l'accord avec Biogen. Est-il trop tard pour acheter des actions APLS ?
- Biogen acquiert Apellis Pharmaceuticals pour 5,6 milliards de dollars, ajoutant des thérapies C3 à son portefeuille
Signaux de trading Signaux d'achat/vente récents avec prix d'entrée et ratio risque/récompense
Mes métriques Votre watchlist personnelle — lignes sélectionnées de Fondamentaux Complets
📊
Choisissez les indicateurs qui vous importent — cliquez sur le ➕ à côté de n'importe quelle ligne dans Fondamentaux Complets ci-dessus.
Votre sélection est enregistrée et vous suit sur tous les tickers.
Détenteurs institutionnels (13F) 1 147 déclarants · $23.5B total · Au 30 juin 2026
Institutions qui déclarent détenir cette action dans leur Formulaire SEC 13F trimestriel. Uniquement les positions longues ; un même déclarant peut apparaître deux fois pour des jambes d'options distinctes. Les jambes put/call compensatoires importantes reflètent généralement la tenue de marché ou un inventaire couvert, pas une conviction directionnelle.
Activité institutionnelle — Q2 2026 vs trimestre précédent
| Nouvelles positions | Positions clôturées | Augmenté | Diminué | Variation nette des actions |
|---|---|---|---|---|
| 133 (-29 vs T. préc.) | 76 (-23 vs T. préc.) | 406 (+25 vs T. préc.) | 295 (-2 vs T. préc.) | +24.3M |
Comparé à Q1 2026. Les dépôts de formulaire 13F de la SEC sont dus dans les 45 jours suivant la fin du trimestre, plus une courte période tampon pour les déposants tardifs — les trimestres encore dans cette fenêtre sont ignorés au profit de la paire la plus récente entièrement déclarée.
| Institution | Valeur | Actions | % de 13F suivies | Type |
|---|---|---|---|---|
| PRIMECAP MANAGEMENT CO/CA/ | $3 274 304 389 | 15 154 606 | 13,94% | Actions |
| VANGUARD GROUP INC | $2 812 686 259 | 15 982 080 | 11,97% | Actions |
| FMR LLC | $2 480 996 199 | 11 482 904 | 10,56% | Actions |
| VANGUARD CAPITAL MANAGEMENT LLC | $2 085 220 339 | 9 651 117 | 8,88% | Actions |
| STATE STREET CORP | $1 586 815 292 | 7 344 327 | 6,75% | Actions |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1 427 062 472 | 6 604 936 | 6,07% | Actions |
| GEODE CAPITAL MANAGEMENT, LLC | $853 425 885 | 3 965 587 | 3,63% | Actions |
| WELLINGTON MANAGEMENT GROUP LLP | $651 741 965 | 3 016 486 | 2,77% | Actions |
| NORGES BANK | $557 441 930 | 2 580 033 | 2,37% | Actions |
| Boston Partners | $237 039 714 | 1 097 693 | 1,01% | Actions |
| Alyeska Investment Group, L.P. | $201 448 726 | 932 374 | 0,86% | Actions |
| Pictet Asset Management Holding SA | $184 144 886 | 851 819 | 0,78% | Actions |
| DIMENSIONAL FUND ADVISORS LP | $183 196 029 | 847 893 | 0,78% | Actions |
| VANGUARD FIDUCIARY TRUST CO | $179 182 447 | 829 318 | 0,76% | Actions |
| Robeco Institutional Asset Management B.V. | $170 923 341 | 791 092 | 0,73% | Actions |
| FRED ALGER MANAGEMENT, LLC | $170 321 610 | 788 307 | 0,73% | Actions |
| BANK OF AMERICA CORP /DE/ | $156 665 322 | 725 101 | 0,67% | Actions |
| Employees Provident Fund Board | $152 148 588 | 704 196 | 0,65% | Actions |
| FIRST TRUST ADVISORS LP | $147 357 277 | 682 021 | 0,63% | Actions |
| AustralianSuper Pty Ltd | $145 348 531 | 672 723 | 0,62% | Actions |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $129 114 863 | 597 588 | 0,55% | Actions |
| BlackRock, Inc. | $124 065 973 | 574 220 | 0,53% | Actions |
| Artemis Investment Management LLP | $123 364 642 | 570 974 | 0,53% | Actions |
| Legal & General Group Plc | $119 267 279 | 552 010 | 0,51% | Actions |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $116 672 616 | 540 001 | 0,50% | Actions |
| Caisse de depot et placement du Quebec | $110 232 516 | 510 194 | 0,47% | Actions |
| UBS Group AG | $108 289 272 | 501 200 | 0,46% | Option d'achat |
| CITADEL ADVISORS LLC | $90 389 997 | 418 356 | 0,38% | Actions |
| Swiss National Bank | $89 427 234 | 413 900 | 0,38% | Actions |
| National Pension Service | $87 734 188 | 406 064 | 0,37% | Actions |
| LMR Partners LLP | $84 047 340 | 389 000 | 0,36% | Option d'achat |
| BNP PARIBAS FINANCIAL MARKETS | $83 732 325 | 387 542 | 0,36% | Actions |
| Candriam S.C.A. | $82 957 583 | 384 326 | 0,35% | Actions |
| ROYAL BANK OF CANADA | $78 304 000 | 362 418 | 0,33% | Actions |
| Mitsubishi UFJ Asset Management Co., Ltd. | $77 527 297 | 358 823 | 0,33% | Actions |
| Sumitomo Mitsui Trust Group, Inc. | $74 890 069 | 346 617 | 0,32% | Actions |
| VICTORY CAPITAL MANAGEMENT INC | $74 199 109 | 343 419 | 0,32% | Actions |
| Fisher Asset Management, LLC | $73 032 374 | 338 018 | 0,31% | Actions |
| Vanguard Global Advisers, LLC | $72 582 332 | 335 936 | 0,31% | Actions |
| California Public Employees Retirement System | $71 106 642 | 329 106 | 0,30% | Actions |
| Swedbank AB | $69 271 861 | 320 614 | 0,29% | Actions |
| CITADEL ADVISORS LLC | $68 058 900 | 315 000 | 0,29% | Option d'achat |
| GOLDMAN SACHS GROUP INC | $63 917 486 | 295 832 | 0,27% | Actions |
| LMR Partners LLP | $62 268 492 | 288 200 | 0,27% | Option de vente |
| VANGUARD ASSET MANAGEMENT, Ltd | $61 442 279 | 284 376 | 0,26% | Actions |
| Patient Capital Management, LLC | $61 295 674 | 283 697 | 0,26% | Actions |
| Gotham Asset Management, LLC | $60 475 194 | 279 900 | 0,26% | Actions |
| CAUSEWAY CAPITAL MANAGEMENT LLC | $60 125 780 | 278 283 | 0,26% | Actions |
| PERCEPTIVE ADVISORS LLC | $59 669 938 | 276 173 | 0,25% | Actions |
| Balyasny Asset Management L.P. | $57 275 345 | 265 090 | 0,24% | Actions |
| RHUMBLINE ADVISERS | $56 819 153 | 262 979 | 0,24% | Actions |
| HSBC HOLDINGS PLC | $52 886 951 | 244 779 | 0,23% | Actions |
| AEGON ASSET MANAGEMENT UK Plc | $52 092 282 | 241 101 | 0,22% | Actions |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $47 304 392 | 218 941 | 0,20% | Actions |
| JANE STREET GROUP, LLC | $47 122 686 | 218 100 | 0,20% | Option de vente |
| KLP KAPITALFORVALTNING AS | $43 034 183 | 199 177 | 0,18% | Actions |
| JANE STREET GROUP, LLC | $41 289 066 | 191 100 | 0,18% | Option d'achat |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $40 458 548 | 220 687 | 0,17% | Actions |
| PANAGORA ASSET MANAGEMENT INC | $40 387 880 | 186 929 | 0,17% | Actions |
| NISSAY ASSET MANAGEMENT CORP /JAPAN | $40 036 134 | 185 301 | 0,17% | Actions |
| PRINCIPAL FINANCIAL GROUP INC | $39 509 594 | 182 864 | 0,17% | Actions |
| ALLIANCEBERNSTEIN L.P. | $39 411 367 | 214 975 | 0,17% | Actions |
| BARCLAYS PLC | $38 890 800 | 180 000 | 0,17% | Option de vente |
| BARCLAYS PLC | $37 038 518 | 171 427 | 0,16% | Actions |
| Quantinno Capital Management LP | $32 836 341 | 151 977 | 0,14% | Actions |
| MORGAN STANLEY | $32 548 902 | 150 647 | 0,14% | Actions |
| LETKO, BROSSEAU & ASSOCIATES INC | $31 666 186 | 146 562 | 0,13% | Actions |
| Portolan Capital Management, LLC | $30 865 467 | 142 856 | 0,13% | Actions |
| Palo Alto Investors LP | $30 308 681 | 140 279 | 0,13% | Actions |
| Walleye Trading LLC | $30 087 003 | 139 253 | 0,13% | Actions |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC | $29 872 456 | 138 260 | 0,13% | Actions |
| Nippon Life Global Investors Americas, Inc. | $29 647 753 | 137 220 | 0,13% | Actions |
| CITADEL ADVISORS LLC | $28 995 252 | 134 200 | 0,12% | Option de vente |
| IEQ CAPITAL, LLC | $28 550 680 | 132 142 | 0,12% | Actions |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $28 001 160 | 129 599 | 0,12% | Actions |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $26 210 455 | 121 311 | 0,11% | Actions |
| AMERICAN CENTURY COMPANIES INC | $24 663 681 | 114 152 | 0,10% | Actions |
| Woodline Partners LP | $24 298 756 | 112 463 | 0,10% | Actions |
| AVIVA PLC | $23 345 715 | 108 052 | 0,10% | Actions |
| Eurizon Capital SGR S.p.A. | $22 171 682 | 102 594 | 0,09% | Actions |
| ADAMS DIVERSIFIED EQUITY FUND, INC. | $21 670 818 | 100 300 | 0,09% | Actions |
| NEW YORK STATE COMMON RETIREMENT FUND | $21 637 329 | 100 145 | 0,09% | Actions |
| UBS Group AG | $21 607 945 | 100 009 | 0,09% | Actions |
| SPHERA FUNDS MANAGEMENT LTD. | $21 606 000 | 100 000 | 0,09% | Option d'achat |
| Balyasny Asset Management L.P. | $21 606 000 | 100 000 | 0,09% | Option d'achat |
| Integral Health Asset Management, LLC | $21 606 000 | 100 000 | 0,09% | Actions |
| Illinois Municipal Retirement Fund | $21 455 406 | 99 303 | 0,09% | Actions |
| Susquehanna Portfolio Strategies, LLC | $21 346 944 | 98 801 | 0,09% | Actions |
| APG Asset Management N.V. | $20 973 675 | 110 984 | 0,09% | Actions |
| SPHERA FUNDS MANAGEMENT LTD. | $20 877 014 | 96 626 | 0,09% | Actions |
| LPL Financial LLC | $20 626 314 | 95 466 | 0,09% | Actions |
| Rhenman & Partners Asset Management AB | $20 493 291 | 94 850 | 0,09% | Actions |
| PEAK6 LLC | $20 374 458 | 94 300 | 0,09% | Option d'achat |
| STRS OHIO | $20 265 132 | 93 794 | 0,09% | Actions |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $19 614 791 | 90 784 | 0,08% | Actions |
| Hudson Bay Capital Management LP | $19 445 400 | 90 000 | 0,08% | Actions |
| VAN ECK ASSOCIATES CORP | $19 191 313 | 88 824 | 0,08% | Actions |
| Point72 Asset Management, L.P. | $19 045 473 | 88 149 | 0,08% | Actions |
| ANTIPODES PARTNERS Ltd | $18 759 842 | 86 827 | 0,08% | Actions |
| MACKENZIE FINANCIAL CORP | $18 666 288 | 86 394 | 0,08% | Actions |
Initiés de la société 83 initiés · 51 dirigeants · 28 administrateurs
| Dirigeant | Rôle | Dernière activité | Actions détenues | Achats 12m | Ventes 12m | Net 12m |
|---|---|---|---|---|---|---|
| Christopher Viehbacher | President and CEO | 13 février 2026 A | 29 924 | 0 | 0 | $0 |
| Michel Vounatsos | Chief Executive Officer | 18 février 2022 J | 67 261 | 0 | 0 | $0 |
| George A Scangos | Chief Executive Officer | 21 juillet 2016 S | 54 779 | 0 | 0 | $0 |
| MULLEN JAMES C | CEO & President | 8 juin 2010 A | 95 503 | 0 | 0 | $0 |
| Robin Kramer | Chief Financial Officer | 13 février 2026 A | 11 472 | 0 | 0 | $0 |
| Michael R. Mcdonnell | EVP, Chief Financial Officer | 10 février 2025 M | 24 341 | 0 | 0 | $0 |
| Jeffrey D Capello | EVP & Chief Financial Officer | 12 février 2020 J | 3 118 | 0 | 0 | $0 |
| Paul J Clancy | Executive VP and CFO | 25 avril 2017 S | 10 813 | 0 | 0 | $0 |
| KELLOGG PETER N | EVP, Finance and CFO | 20 mars 2007 S | 18 966 | 0 | 0 | $0 |
| Robert A Hamm | Chief Operating Officer | 23 avril 2010 S | 27 212 | 0 | 0 | $0 |
| HASLER HANS PETER | Chief Operating Officer | 24 février 2009 A | 53 261 | 0 | 0 | $0 |
| William R Rohn | Chief Operating Officer | 17 novembre 2004 M | 65 462 | 0 | 0 | $0 |
| Adam Keeney | Head of Corporate Development | 1 mai 2026 M | 6 365 | 0 | 0 | $0 |
| Sean Godbout | Chief Accounting Officer | 1 avril 2026 M | 1 342 | 0 | 0 | $0 |
| Jane Grogan | Head of Research | 13 février 2026 A | 4 058 | 0 | 0 | $0 |
| Nicole Murphy | Head of Pharm Ops and Tech | 13 février 2026 A | 19 611 | 1 | 0 | $585 |
| Rachid Izzar | Head of Global Product Strat. | 13 février 2026 A | 11 011 | 0 | 0 | $0 |
| Singhal Priya | Head of Development | 13 février 2026 A | 8 043 | 0 | 3 | $-734 709 |
| Ginger Gregory | EVP, Human Resources | 13 février 2026 A | 22 359 | 0 | 0 | $0 |
| Susan H Alexander | EVP Chief Legal Officer | 13 février 2026 A | 41 807 | 0 | 0 | $0 |
| Chirfi Guindo | Head of Glob Prod Strat & Com | 18 février 2022 J | 7 364 | 0 | 0 | $0 |
| Alphonse Galdes | EVP Pharmaceutical Oper & Tech | 19 janvier 2022 A | 5 064 | 0 | 0 | $0 |
| Alfred Sandrock | Head of Research & Development | 7 juin 2021 S | 10 169 | 0 | 0 | $0 |
| Daniel Karp | EVP, Corporate Development | 12 février 2020 A | 930 | 0 | 0 | $0 |
| Michael D Ehlers | EVP, Research and Development | 1 juin 2019 J | 8 025 | 0 | 0 | $0 |
| Paul Mckenzie | EVP Pharmaceutical Oper & Tech | 1 mars 2019 J | 7 235 | 0 | 0 | $0 |
| Gregory F Covino | VP, Chief Accounting Officer | 1 mars 2018 A | 4 744 | 0 | 0 | $0 |
| Jean-Paul Kress | EVP Pres Int'l & Global Hd GTO | 3 juillet 2017 A | — | 0 | 0 | $0 |
| Adriana Karaboutis | EVP, Tech, Bus. Sol & Corp Aff | 28 février 2017 M | 8 752 | 0 | 0 | $0 |
| Kenneth Dipietro | EVP Human Resources | 28 février 2017 J | 7 177 | 0 | 0 | $0 |
| Adam Koppel | EVP, Strategy and Bus. Dev. | 6 juin 2016 S | 2 402 | 0 | 0 | $0 |
| Spyridon Artavanis-Tsakonas | EVP, Chief Scientific Officer | 2 avril 2016 M | 3 150 | 0 | 0 | $0 |
| John Cox | EVP Pharmaceutical Oper & Tech | 1 avril 2016 A | 39 045 | 0 | 0 | $0 |
| Steven H Holtzman | EVP Corporate Development | 23 février 2016 J | 8 326 | 0 | 0 | $0 |
| Douglas E Williams | EVP Research & Development | 19 juin 2015 S | 11 817 | 0 | 0 | $0 |
| Stuart A Kingsley | EVP, Global Comm. Operations | 23 février 2015 A | 8 132 | 0 | 0 | $0 |
| Raymond Pawlicki | SVP, Chief Information Officer | 22 novembre 2013 M | 8 710 | 0 | 0 | $0 |
| Robert E. Gagnon | Vice President, Finance | 29 février 2012 S | 3 999 | 0 | 0 | $0 |
| Francesco Granata | EVP Global Commercial Operatio | 1 février 2012 M | 3 529 | 0 | 0 | $0 |
| SCHNEIER CRAIG ERIC | EVP, HR, Public Affairs & Comm | 1 mars 2011 M | 10 201 | 0 | 0 | $0 |
| Michael F Maclean | SVP, Chief Accounting Officer | 1 octobre 2010 F | 10 681 | 0 | 0 | $0 |
| Michael Lytton | EVP Corporate & Business Devel | 2 mars 2010 F | 18 869 | 0 | 0 | $0 |
| Mark C Wiggins | EVP Corp. and Bus. Dev. | 26 septembre 2008 S | 22 780 | 0 | 0 | $0 |
| Faheem Hasnain | EVP, Oncology/Rheumatology SBU | 9 juillet 2008 M | 25 454 | 0 | 0 | $0 |
| ADELMAN BURT A | EVP, Portfolio Strategy | 15 octobre 2007 M | 12 769 | 0 | 0 | $0 |
| Michael Kowolenko | SVP, Pharm Ops & Technology | 25 juillet 2007 M | 18 124 | 0 | 0 | $0 |
| Connie Matsui | EVP, Corp. Strategy and Comm. | 12 février 2007 A | 22 837 | 0 | 0 | $0 |
| William H Rastetter | Executive Chairman | 23 février 2005 J | 373 929 | 0 | 0 | $0 |
| Michael Gilman | EVP - Research | 17 février 2005 A | 23 000 | 0 | 0 | $0 |
| BUCKNUM THOMAS J | EVP and General Counsel | 17 février 2005 A | 5 750 | 0 | 0 | $0 |
Initiés issus des déclarations SEC Form 3/4/5 ; net = uniquement P/S de marché
Activistes et détenteurs de 5%+ 7 participations
Investisseurs ayant déposé un Schedule 13D auprès de la SEC — détention effective supérieure à 5% avec l'intention d'influencer l'émetteur (participations activistes, campagnes pour le conseil d'administration, fusions-acquisitions). Chaque ligne montre le dernier état connu de la position du déposant.
| Déclarant | Déposé | Participation | Statut | Objectif | Dépôt |
|---|---|---|---|---|---|
| Biogen Inc. ×8 dépôts | 14 mai 2026 | 0,00% | Amendement | Fusions et acquisitions / vente | SEC |
| High River Limited Partnership, Hopper Investments LLC, Barberry Corp., Icahn Partners Master Fund LP, Icahn Partners Master Fund II LP, Icahn Partners Master Fund III LP, Icahn Offshore LP, Icahn Partners LP, Icahn Onshore LP, Icahn Capital LP, IPH GP LLC, Icahn Enterprises Holdings L.P., Icahn Enterprises G.P. Inc., Beckton Corp., Carl C. Icahn ×4 dépôts | 22 juin 2011 | — | Dépôt initial | — | SEC |
| 22 mars 2010 | — | Dépôt initial | — | SEC | |
| Personne déclarante non divulguée, Personne déclarante non divulguée, Personne déclarante non divulguée, Personne déclarante non divulguée, Personne déclarante non divulguée | 28 janvier 2010 | — | Dépôt initial | — | SEC |
| AND | 8 mai 2008 | — | Dépôt initial | — | SEC |
| Biogen Idec Inc., Biogen Idec MA Inc. ×3 dépôts | 9 novembre 2006 | — | Dépôt initial | Fusions et acquisitions / vente | SEC |
| Personne déclarante non divulguée, Personne déclarante non divulguée | 14 février 2001 | — | Dépôt initial | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Détention d'ETF Détenu par 199 ETFs
Le poids reflète uniquement les participations directes en actions (N-PORT) ; les fonds à effet de levier ou basés sur des dérivés peuvent détenir une exposition supplémentaire aux swaps non indiquée.
| Fonds | Poids | Unités | Au | Source |
|---|---|---|---|---|
| PBE · Invesco Exchange-Traded Fund Trust | 4,72% | 82 332 SH | 8 août 2026 | Quotidien |
| IBRN · iShares Trust | 4,02% | 1 505 SH | 8 août 2026 | Quotidien |
| PJP · Invesco Exchange-Traded Fund Trust | 2,74% | 66 627 SH | 8 août 2026 | Quotidien |
| IBB · iShares Trust | 2,33% | 1 074 761 SH | 8 août 2026 | Quotidien |
| FXH · First Trust Exchange-Traded AlphaDE… | 2,23% | 103 216 NS | 30 avril 2026 | N-PORT |
| SPIT · RBB Fund, Inc. | 2,11% | 3 185 NS | 30 avril 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 2,09% | 8 035 SH | 8 août 2026 | Quotidien |
| BBP · ETFis Series Trust I | 1,73% | 5 434 NS | 30 avril 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,62% | 61 078 SH | 8 août 2026 | Quotidien |
| QQQJ · Invesco Exchange-Traded Fund Trust … | 1,48% | 84 204 SH | 8 août 2026 | Quotidien |
| BIB · ProShares Trust | 1,44% | 5 425 NS | 31 mai 2026 | N-PORT |
| TMFX · RBB Fund, Inc. | 1,39% | 2 280 NS | 31 mai 2026 | N-PORT |
| CVAR · ETF Opportunities Trust | 1,34% | 2 744 NS | 30 avril 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 1,30% | 764 NS | 30 avril 2026 | N-PORT |
| NUMV · Nushares ETF Trust | 1,01% | 23 096 NS | 30 avril 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,93% | 25 484 NS | 30 avril 2026 | N-PORT |
| SPVM · Invesco Exchange-Traded Fund Trust | 0,88% | 5 573 SH | 8 août 2026 | Quotidien |
| ABCS · EA Series Trust | 0,75% | 431 NS | 29 mai 2026 | N-PORT |
| FBCV · FIDELITY COVINGTON TRUST | 0,74% | 6 263 NS | 30 avril 2026 | N-PORT |
| FLRG · FIDELITY COVINGTON TRUST | 0,73% | 10 857 NS | 30 avril 2026 | N-PORT |
| FTA · First Trust Exchange-Traded AlphaDE… | 0,72% | 49 392 NS | 30 avril 2026 | N-PORT |
| AVMV · AMERICAN CENTURY ETF TRUST | 0,70% | 22 249 NS | 31 mai 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 0,69% | 558 NS | 30 avril 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 0,67% | 642 650 NS | 30 avril 2026 | N-PORT |
| QQWZ · Pacer Funds Trust | 0,66% | 1 636 NS | 30 avril 2026 | N-PORT |
| ITAN · EA Series Trust | 0,59% | 2 701 NS | 29 mai 2026 | N-PORT |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0,58% | 18 519 NS | 30 avril 2026 | N-PORT |
| VOE · VANGUARD INDEX FUNDS | 0,55% | 948 376 SH | 8 août 2026 | Quotidien |
| IYH · iShares Trust | 0,50% | 88 325 SH | 8 août 2026 | Quotidien |
| RCGE · EA Series Trust | 0,48% | 2 389 NS | 30 avril 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,47% | 441 144 SH | 8 août 2026 | Quotidien |
| FHLC · FIDELITY COVINGTON TRUST | 0,45% | 67 622 NS | 30 avril 2026 | N-PORT |
| RPV · Invesco Exchange-Traded Fund Trust | 0,43% | 35 530 SH | 8 août 2026 | Quotidien |
| IMCV · iShares Trust | 0,42% | 23 383 SH | 8 août 2026 | Quotidien |
| RXL · ProShares Trust | 0,42% | 1 530 NS | 31 mai 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0,40% | 2 927 NS | 30 avril 2026 | N-PORT |
| IXJ · iShares Trust | 0,38% | 77 453 SH | 8 août 2026 | Quotidien |
| BSCU · Invesco Exchange-Traded Self-Indexe… | 0,37% | 10 761 000 | 8 août 2026 | Quotidien |
| FAB · First Trust Exchange-Traded AlphaDE… | 0,36% | 2 605 NS | 30 avril 2026 | N-PORT |
| AVMC · AMERICAN CENTURY ETF TRUST | 0,35% | 7 256 NS | 31 mai 2026 | N-PORT |
| FEX · First Trust Exchange-Traded AlphaDE… | 0,34% | 26 804 NS | 30 avril 2026 | N-PORT |
| VLUE · iShares Trust | 0,33% | 149 494 SH | 8 août 2026 | Quotidien |
| VO · VANGUARD INDEX FUNDS | 0,31% | 3 199 564 SH | 8 août 2026 | Quotidien |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0,29% | 6 727 NS | 30 avril 2026 | N-PORT |
| IWS · iShares Trust | 0,29% | 222 364 SH | 8 août 2026 | Quotidien |
| GINN · Goldman Sachs ETF Trust | 0,27% | 2 960 NS | 31 mai 2026 | N-PORT |
| FLCV · Federated Hermes ETF Trust | 0,27% | 1 332 NS | 31 mai 2026 | N-PORT |
| CLSE · Trust for Professional Managers | 0,26% | 8 169 NS | 31 mai 2026 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0,26% | 8 407 SH | 8 août 2026 | Quotidien |
| AVIE · AMERICAN CENTURY ETF TRUST | 0,26% | 136 NS | 31 mai 2026 | N-PORT |